Niox Group PLC (NIOX), the medical device company focused on airway inflammation diagnostics, has received a major shareholding notification from Artemis Investment Management LLP, a London-based fund manager. The TR-1 disclosure, filed with the company on 9 November 2026, confirms that Artemis crossed the 5% voting rights threshold in Niox Group on 6 November 2026. The notification means Artemis now holds 20,517,107 shares, representing 5.062538% of Niox Group's total voting rights, a level that triggers mandatory disclosure under UK Disclosure and Transparency Rules.

Key Points

  • Niox Group PLC (NIOX) — medical diagnostics company listed in the UK
  • Artemis Investment Management LLP has crossed the 5% voting rights threshold in Niox Group PLC
  • Artemis holds 20,517,107 voting rights, equating to 5.062538%, as at 6 November 2026
  • Investors may be watching whether Artemis increases or reduces its position in subsequent disclosures

Artemis Investment Management Holds 20,517,107 Niox Group Shares Via Indirect Route

The TR-1 form confirms that Artemis Investment Management LLP holds its entire 20,517,107-share position indirectly, with the voting rights attributed under DTR5.2.1 rather than as a direct holding. The shares carry ISIN code GB00BJVD3B28, identified as equity in Niox Group PLC. The disclosure further notes that Artemis Fund Managers Limited sits within the chain of controlled undertakings, with both entities recording the same 5.062538% total voting rights figure. No financial instruments, options, or cash-settled instruments form part of this holding, meaning the entire position is held through direct equity shares managed on behalf of clients.

Threshold Crossed on 6 November 2026 Through Acquisition or Disposal of Voting Rights

According to the announcement, the reason for notification is recorded as an acquisition or disposal of voting rights, indicating a change in the size of Artemis's holding relative to the 5% statutory threshold. The threshold crossing date is recorded as 6 November 2026, with the issuer notified three days later on 9 November 2026, in line with standard regulatory timelines under UK Disclosure and Transparency Rules. No previous notification position is detailed within the filing, so the announcement does not confirm whether this represents a new position or a movement across the threshold from a prior holding.

Niox Group's Airway Diagnostics Focus Attracts Institutional Attention From Artemis

Niox Group PLC develops and commercialises devices used to measure fractional exhaled nitric oxide, a clinical marker used in the diagnosis and monitoring of airway inflammation conditions such as asthma. The company operates internationally, with its NIOX VERO device used across healthcare settings globally. Institutional interest of this scale from an established UK fund manager such as Artemis Investment Management, which is registered in London and completes filings from its Edinburgh office, may draw attention from investors monitoring the shareholder register. The company did not disclose any operational or financial updates alongside this regulatory notification.